Compare BHR & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | MXCT |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.7M | 136.2M |
| IPO Year | 2013 | 2021 |
| Metric | BHR | MXCT |
|---|---|---|
| Price | $1.65 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.11 |
| AVG Volume (30 Days) | ★ 426.1K | 325.0K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $487,614,000.00 | $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $28.00 | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.64 | $0.64 |
| 52 Week High | $3.19 | $1.86 |
| Indicator | BHR | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 25.65 | 41.47 |
| Support Level | N/A | $1.11 |
| Resistance Level | $2.63 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.77 | 15.38 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.